Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Obstetrics/Gynecology | Endocrinology

Ovarian Cancer

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

California

Anaheim : Pacific Cancer Medical Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Anaheim : Pacific Cancer Medical Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Corona : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Corona : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Duarte : City of Hope

Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer

Duarte : City of Hope

Randomized Pilot Trial of Oral Cyclophosphamide versus Oral Cyclophosphamide with Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fountain Valley : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Fountain Valley : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Newport Beach : Gynecologic Oncology Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Newport Beach : Gynecologic Oncology Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Pleasant : Bay Area Cancer Research Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Pleasant : Bay Area Cancer Research Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Riverside : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Riverside : Compassionate Cancer Care Medical Group

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Colorado

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Englewood : Rocky Mountain Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Englewood : Rocky Mountain Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Florida

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Port Rich : Research Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

New Port Rich : Research Site

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

West Palm Beach : Palm Beach Cancer Center

Phase 2 study to evaluate the efficacy and safety of NKTR 102 (PEG-Irinotecan) when given on a Q14 day or a Q21 day schedule in patients with metastatic or locally advanced platinum-resistant ovarian cancer

Georgia

Athens : Northeast Georgia Cancer Care, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Athens : Northeast Georgia Cancer Care, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Athens : Southeastern Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Atlanta : Southeastern Gynecologic Oncology

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Augusta : Medical College of Georgia

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Augusta : Medical College of Georgia

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Savannah : Memorial Health University Medical Center

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Savannah : Memorial Health University Medical Center

ChemoFx® Observational Study in Gynecological Solid Tumors

Savannah : Memorial Health University Medical Center

GOG-136: Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer

Savannah : Memorial Health University Medical Center

MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Illinois

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Gurnee : Oncology Hematology Associates of Northern Illinois

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Gurnee : Oncology Hematology Associates of Northern Illinois

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Indiana

Beech Grove : St. Francis Hospital and Health Centers

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)

Kansas

Witcha : Cancer Center of Kansas

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Witcha : Cancer Center of Kansas

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Missouri

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Jersey

Morristown : Atlantic Health System

A Study Comparing the Combination of Doxil and Yondelis, to Doxil Alone for Subjects With Ovarian Cancer

Morristown : Atlantic Health System

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)

Morristown : Atlantic Health System

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York

Brightwaters : Biomedical Research Alliance of New York

Safety and Effectiveness of an Experimental drug for Reducing the Side-Effects of Chemotherapy Given for Recurrent Ovarian Cancer – Adults

Bronx : Biomedical Research Alliance of New York

Abnormal Pelvic Mass - Adults

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-line and Second-line Therapy

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York : Mount Sinai Medical Center

A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989, IND #70,252) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [GOG-0170-G]

New York : Mount Sinai Medical Center

A Phase II Evaluation of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338)) in Combination with Cisplatin (Commercially Available: NSC #119875) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma [GOG 0126-o]

New York : Mount Sinai Medical Center

A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Woman who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries [GOG0215]

New York : Mount Sinai Medical Center

A Randomized Study of Tamoxifen Versus Thalidomide (NSC# 66847) in Patients with Biochemical-Recurrence-Only-Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy [GOG-0198]

New York : Mount Sinai Medical Center

An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma [GOG0190]

New York : Mount Sinai Medical Center

Prospective Study of Risk-Reducing Salpingo-Ophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer [GOG 0199]

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Oklahoma

Tulsa : Cancer Care Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Tulsa : Cancer Care Associates

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tennessee

Chattanooga : Tennessee GYN Oncology Group, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Chattanooga : Tennessee GYN Oncology Group, LLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Knoxville : Hall and Martin MDs, PC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Knoxville : Hall and Martin MDs, PC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Texas

Amarillo : Harrington Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Amarilo : Harrington Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Austin : Southwest Regional Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Austin : Southwest Regional Cancer Center

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Ovary

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Uterine Cervix And/Or Vulva

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplastons A10 And AS2-1In Patients With Adenocarcinoma Of The Stomach

San Antonio : South Texas Oncology & Hematology PA

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

San Antonio : South Texas Oncology & Hematology PA

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Virginia

Charlottesville : University of Virginia New!

Women ages 18 and above at high risk for Ovarian Cancer planning to undergo removal of both ovaries needed for research study.

Charlottesville : University of Virginia New!

Women who plan to have their ovaries removed sought for research study.

Charlottesville : University of Virginia New!

Women with Ovarian or Peritoneal Cancer Sought for Research Study.

Washington

Olympia : Capital Oncology, PLLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Olympia : Capital Oncology, PLLC

Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Australia

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Belgium

Bruxelles : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Leuven : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Wilrijk : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Brazil

Jaú : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Sao Paulo : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Canada

Calgary, AB : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Kelowna, BC : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Vancouver, BC : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

France

Ales : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Amiens : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Avignon : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Avignon : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bordeaux : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Bordeaux : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Brive : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Brive : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Caen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Clamart : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Dax : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Dijon : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Gap : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Grenoble : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Grenoble : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Le Chesnay : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lille : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lyon : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Marseille : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Mont-De-Marsan : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Montpellier : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Mougins : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nancy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nantes : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nice : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Nice : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nimes : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Orleans : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Paris : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Paris : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Perigueux : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Poitiers : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Pringy : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Pringy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Reims : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Rouen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint Brieuc : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint Nazaire : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint-Cloud : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Saint-Priest-En-Jarez : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Strasbourg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Strasbourg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Thonon-Les-Bains : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Toulouse : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Valenciennes : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Vandoeuvre-Les-Nancy : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Vandoeuvre-Les-Nancy : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Germany

Berlin : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bremen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Düsseldorf : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Erlangen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Essen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Frankfurt Am Main : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hamburg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hannover : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hildesheim : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kassel : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kiel : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Krefeld : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Lübeck : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Mannheim : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

München : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Nürnberg : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Offenbach : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Recklinghausen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Rostock : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Stuttgart : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Tübingen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Ulm : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Wiesbaden : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Hungary

Budapest : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Debrecen : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Gyor : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Italy

Aviano : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Bergamo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Campobasso : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Milano : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Milano : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Modena : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Napoli : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Palermo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Parma : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Roma : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Roma : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Torino : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Trento : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Udine : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Netherlands

Alkmaar : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Amsterdam : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Amsterdam : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Apeldoorn : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Enschede : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Groningen : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Leiden : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Leidschendam : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Tilburg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Zwolle : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Norway

Bergen : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Bergen : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Oslo : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Oslo : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Trondheim : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Poland

Gdansk : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Poznan : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Poznan : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Warszawa : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Warszawa : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Portugal

Lisboa : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Porto : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Russian Federation

Kazan : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Krasnodar : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Moscow : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Moscow : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

St Petersburg : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Stavropol : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Tomsk : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Spain

Barcelona : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Barcelona : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Madrid : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Madrid : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Madrid : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Málaga : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Valencia : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Valencia : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Sweden

Goeteborg : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Linkoeping : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Linkoeping : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Örebro : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Örebro : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Umea : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Umea : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Uppsala : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Uppsala : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Switzerland

Chur : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Turkey

Adana : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Istanbul : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Kocaeli : Research Site:

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

United Kingdom

Birmingham : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

London : Research Site:

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

London : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Manchester : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Plymouth : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Sutton : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

Yeovil : Research Site:

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer